Editas names Reeve chair, adds Levy to board

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) appointed Emma Reeve chair as James Mullen steps down as executive chair. Reeve, who joined the board in September 2021, was CFO at Constellation Pharmaceuticals Inc. and interim CFO and corporate controller at Parexel International Corp. The company also named Elliott Levy to the board; Levy was SVP and head of global development and R&D strategy and operations at Amgen Inc. (NASDAQ:AMGN).

Exelixis Inc. (NASDAQ:EXEL) is recommending Tomas Heyman and Robert Oliver to succeed departing board members Carl Feldbaum and Vincent Marches as it continues to grapple with the demands of activist investor Farallon Capital Management. Exelixis said its board agreed to appoint Heyman and Oliver as part of a proposed deal with Farallon, which proposed the pair, but that the firm insisted on a “highly unusual breadth and depth” of access to the company’s confidential information as part of the agreement — a request that Exelixis declined. Heyman is CEO of Interlaken Therapeutics Inc. and was president of the venture group at Johnson & Johnson (NYSE:JNJ); Oliver was president of the U.S. unit of Otsuka Holdings Co. Ltd. (Tokyo:4578)...